Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Randomized Study Comparing Partial Versus Whole Breast Irradiation in Women with Early Breast Cancer
Researchers are evaluating radiation treatments for women with small, node-negative invasive breast cancer measuring 3 cm or less. This trial compares partial breast irradiation PBI to whole breast irradiation WBI, both given once daily over about one week after breast-conserving surgery. The main goal is to see if PBI is not worse than WBI for preventing local cancer recurrence and if it improves cosmetic outcomes, as judged by patients, three years after treatment. Participants are randomly assigned to receive either PBI or WBI. Both groups receive a total radiation dose of 26 Gy split into five daily treatments over 5 to 7 days, with a possible extension to 8 days due to scheduling. The WBI targets the entire breast, while PBI focuses radiation on the tumor bed plus a margin of normal tissue. Patients are not informed which treatment they receive to avoid bias in assessing cosmetic results. Key factors such as tumor size, estrogen receptor status, and treatment center are used for group assignment. During the study, participants will be monitored annually for five years to assess local recurrence, distant disease-free survival, overall survival, and radiation side effects. Cosmetic outcomes will be evaluated by both patients and clinical staff at 3 and 5 years. Quality of life will also be measured at multiple time points. The study lasts several years, with primary outcomes assessed at three years and continued follow-up through at least five years post-treatment.
Actively Recruiting
Researchers are evaluating the safety and preliminary effectiveness of a drug called DB-1311 combined with BNT327 or DB-1305 in adults with various advanced or metastatic solid tumors. This phase II, open-label study includes participants with types of cancer such as hepatocellular carcinoma, cervical cancer, melanoma, head and neck squamous cell carcinoma, ovarian cancer resistant or sensitive to platinum, non-small cell lung cancer, pancreatic ductal carcinoma, breast cancer, colorectal cancer, and metastatic castration-resistant prostate cancer. The purpose is to find suitable doses and assess treatment responses in these targeted groups. Participants receive intravenous doses of DB-1311 combined with either BNT327 or DB-1305. The trial has two parts Part 1 focuses on dose escalation to establish recommended doses, and Part 2 evaluates treatment effects at these doses across different cancer types. Multiple study arms correspond to different combinations and cancer subtypes, with ongoing treatment until study end or discontinuation. The study is conducted at multiple centers and is randomized but open-label. During the study, participants undergo assessments including tumor measurements based on RECIST criteria, safety monitoring for adverse events, and laboratory tests measuring drug levels and immune responses. Researchers track outcomes like dose limiting toxicities, objective response rates, duration of response, overall survival, progression-free survival, and specific cancer markers such as cancer antigen 125 and prostate-specific antigen. The study may last up to 72 months, with long-term follow-up and safety evaluations throughout.
Actively Recruiting
Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.
Actively Recruiting
Long-Term Safety Study of Nivolumab and Other Cancer Therapies in Patients from BMS-Sponsored Trials
Researchers are examining the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This phase 2 study focuses on patients who have previously participated in Bristol-Myers Squibb-sponsored trials involving nivolumab and other cancer treatments. The goal is to monitor safety outcomes over an extended period while patients continue or resume treatment. Participants receive specified doses of nivolumab alone or in combination with other drugs such as ipilimumab, cabozantinib, trametinib, relatlimab, capecitabine, bevacizumab, temozolomide, and others according to their assigned study group. The study includes multiple experimental arms with different drug combinations and dosing schedules, all delivered as drug treatments. Participants continue treatment based on eligibility from their parent studies, including those who are on treatment hold or eligible for rechallenge. Throughout the study, participants undergo regular safety assessments to monitor adverse events, serious adverse events, immune-mediated effects, and any events leading to treatment discontinuation. Monitoring begins from the first day of treatment and continues up to 135 days after treatment ends. Researchers also track incidences of death during this period. The total participation duration spans from enrollment through ongoing treatment and post-treatment safety follow-up, with data collected to evaluate long-term treatment safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two drug combinations for treating patients with hormone receptor-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. This phase 3, open-label, global study compares RLY-2608 zovegalisib plus fulvestrant against capivasertib plus fulvestrant following disease recurrence or progression after prior treatment with a CDK46 inhibitor. The study focuses on patients whose cancer has advanced locally or metastasized and have specific genetic mutations influencing treatment response. Participants will receive one of two treatment combinations zovegalisib taken orally twice daily together with fulvestrant given by intramuscular injection on specified days in a 28-day cycle, or capivasertib taken orally twice daily on an intermittent weekly schedule combined with the same fulvestrant regimen. Treatment cycles repeat every 28 days. The study will monitor and compare these combinations over several months to assess outcomes. Throughout the study, participants will undergo regular assessments including imaging scans to measure cancer progression, blood tests to monitor drug levels, and questionnaires to evaluate quality of life. Researchers will track progression-free survival, overall survival, response rates, duration of response, clinical benefit, and safety profiles. The study duration may extend up to approximately 77 months, with ongoing monitoring of health status and adverse events to gather comprehensive data on treatment impact.
Actively Recruiting
Researchers are studying whether Magnetic Resonance Imaging MRI results can help identify women with early breast cancer who might safely skip radiotherapy after surgery without increasing the chance of cancer returning in the same breast. This international follow-up study, called PROSPECTIVE, builds on earlier research suggesting that MRI combined with pathology can select patients with low-risk breast cancer who may not need radiotherapy. The study also looks at patient quality of life, fear of cancer recurrence, and health economics related to omitting radiotherapy. Participants are divided into two groups based on their MRI and pathology results before surgery. Those with minimal or mild breast changes on MRI and meeting certain pathology criteria may be assigned to Arm A, where radiotherapy is omitted. Arm A is further divided into low-risk and high-risk groups based on cancer grade and HER2 status. Participants not meeting these criteria, or those preferring standard care, receive radiotherapy as part of Arm B. Treatment decisions consider MRI findings, pathology details, and patient or clinical team preferences. During the study, participants undergo regular follow-up for up to 10 years to monitor if cancer returns in the same breast or elsewhere. Researchers assess outcomes including invasive recurrence rates, quality of life, fear of recurrence, mental health, and survival. Patient-reported outcomes are collected at multiple timepoints up to five years post-surgery. The long-term follow-up helps evaluate the safety and impact of omitting radiotherapy in selected patients with early breast cancer.
Actively Recruiting
Researchers are evaluating the safety of omitting adjuvant whole breast radiation therapy WBRT in women with breast cancer who have no clinical lymph node involvement and have achieved a complete pathological response after neoadjuvant chemotherapy. This prospective, multi-center, single arm cohort study focuses on women with newly diagnosed T1-3 node negative breast cancer treated with breast conserving surgery and axillary staging. The study aims to observe breast tumor recurrence and survival outcomes over a median 5-year follow-up period. Participants will not receive the standard adjuvant WBRT after surgery. Instead, they will be closely monitored for any recurrence or progression of breast cancer. The study includes women who have undergone a minimum of eight weeks of neoadjuvant chemotherapy, breast conserving surgery with complete tumor bed excision, and axillary staging surgery. The absence of residual invasive or in situ cancer pathological complete response in the breast and lymph nodes is required for enrollment. During the study, participants will be followed regularly to assess ipsilateral breast tumor recurrence, local and regional recurrence, distant recurrence, disease-free survival, and overall survival. Any additional treatments received for recurrence such as repeat surgery, systemic therapy, or radiation will be documented. The total study duration extends up to five years from enrollment, with researchers evaluating tumor recurrence as the primary outcome at the median five-year mark.
Actively Recruiting
Researchers are investigating the best treatment approaches for infections in artificial hip and knee joints. This study compares different surgical methods, antibiotic choices, and durations of antibiotic treatment to determine which combinations lead to the best outcomes and cure rates at 12 months. The trial focuses on adults with infected artificial joints and aims to address the significant health and economic impacts of prosthetic joint infections. Participants may receive one of several surgical strategies cleaning the infected joint without removing the implant DAIR, or revision surgery where the infected implant is replaced either in a single operation or two stages. Antibiotic treatments are also compared, with some participants receiving standard antibiotics alone and others receiving additional rifampicin. The study further explores different lengths of antibiotic courses after revision surgery, including shorter and longer durations and extended prophylaxis after two-stage revisions. During the study, participants consent to have their medical and treatment information collected in a central database and registry. Researchers will assess health status, infection cure, joint function, quality of life, and antibiotic use at 100 days and 12 months after starting the study. Outcomes like reinfection, survival, and revision surgeries will be monitored up to two years. This study does not require extra tests or treatments beyond routine care and follows participants closely to evaluate treatment success and safety.
Actively Recruiting
Researchers are evaluating the effects of DONQ52 on small intestinal damage and celiac-related symptoms in people with active celiac disease who are trying to maintain a gluten-free diet. This Phase II study compares the effects of DONQ52 with a placebo in participants who have ongoing duodenal mucosal damage and persistent symptoms despite following a gluten-free diet. The goal is to see how DONQ52 influences intestinal healing and symptom reduction related to gluten exposure. Participants receive either DONQ52 or a placebo through subcutaneous injections, combined with oral capsules simulating inadvertent gluten exposure SIGE. The study lasts 27 weeks, during which participants maintain their gluten-free diet and follow the protocol for taking the study treatments. Two upper gastrointestinal endoscopies with duodenal biopsies are performed to assess intestinal damage. Throughout the study, participants undergo regular assessments including symptom diaries for gastrointestinal symptoms, blood tests to monitor drug levels and immune responses, and safety evaluations for adverse events. The primary measure is the change in the villous height to crypt depth ratio over 27 weeks, indicating intestinal healing. Additional measurements track symptom changes and immune reactions up to 47 weeks, ensuring long-term monitoring of treatment effects and safety.
Actively Recruiting
Researchers are evaluating trastuzumab deruxtecan T-DXd for adults with unresectable or metastatic breast cancer that is either HER2-low or HER2 IHC 0. This includes patients with hormone receptor-negative and hormone receptor-positive types. The study aims to assess the safety and effectiveness of T-DXd, focusing on how long patients benefit from this treatment before needing the next anticancer therapy. Participants receive T-DXd intravenously at a dose of 5.4 mgkg on the first day of each 21-day cycle. Treatment continues until disease progression, unacceptable side effects, other criteria for stopping, or two years after the first dose. The study includes four groups based on hormone receptor status and HER2 classification, with participants having had one to two prior treatments for metastatic breast cancer. During the study, participants will have regular assessments including imaging scans to measure tumors, blood tests to monitor organ function, and questionnaires to evaluate quality of life. Researchers will track the time to next treatment, progression-free survival, response rates, adverse events, and changes in patient-reported outcomes for up to 24 months. Safety monitoring and close follow-up will support participant well-being throughout the trial.